CDKL5 Deficiency Disorder and Associated Neurodevelopmental Phenotypes

CDKL5 deficiency disorder (CDD) is a rare X-linked developmental and epileptic encephalopathy characterised by early-onset, treatment-resistant seizures, profound neurodevelopmental impairment and a spectrum of motor, cognitive and behavioural challenges. Mutations in the gene encoding the cyclin-dependent kinase-like 5 (CDKL5) protein disrupt key signalling pathways in the developing brain, leading to abnormal neuronal morphology, synaptic dysfunction and an imbalance between excitation and inhibition. Clinically, affected individuals exhibit severe hypotonia, visual impairment, sleep disturbances, gastrointestinal dysmotility and often autistic features. The disorder shows considerable variability in milestone attainment, with some rare individuals achieving limited motor skills but most remaining non-ambulant and non-verbal. Pathologically, studies in animal and cellular models have revealed deficits in dendritic arborisation, altered microtubule dynamics and aberrant neurotransmitter receptor function. Together these findings underscore CDD as a distinct neurodevelopmental entity with overlapping features of other epilepsy-associated syndromes but unique mechanistic underpinnings and clinical needs.

Research from Nature Portfolio

Recent studies have identified direct molecular targets of CDKL5 and linked their dysregulation to neuronal hyperexcitability. In one report, phosphoproteomic profiling revealed that CDKL5 phosphorylates the Cav2.3 voltage-gated calcium channel, and loss of this regulation results in delayed channel inactivation, enhanced cholinergic responsiveness and increased neuronal firing. This work indicates that CDD may be partly a channelopathy and suggests that Cav2.3 inhibitors could offer therapeutic benefit. Another foundational investigation demonstrated that loss of CDKL5 in GABAergic neurons leads to autistic-like behaviours in mouse models, accompanied by excessive glutamatergic transmission and elevated postsynaptic NMDA receptor levels. Remarkably, low-dose NMDA receptor antagonism ameliorated social deficits and hyperactivity in these animals, highlighting a circuit-based strategy to mitigate core symptoms of CDD.

CDKL5 Deficiency Disorder and Associated Neurodevelopmental Phenotypes publication trend

The graph below shows the total number of articles in cdkl5 deficiency disorder and associated neurodevelopmental phenotypes across all publications each year (not limited to Nature Index journals).

Technical terms

CDKL5: A serine/threonine kinase crucial for normal neuronal development and synaptic function.

Developmental and epileptic encephalopathy (DEE): A group of disorders marked by refractory seizures and developmental impairment arising in infancy or early childhood.

Phosphorylation: The enzymatic addition of a phosphate group to a protein, modulating its activity or interactions.

Voltage-gated calcium channel Cav2.3: A pore-forming protein that mediates calcium influx in response to membrane depolarisation, influencing neuronal excitability.

NMDA receptor: A subtype of glutamate receptor that controls synaptic plasticity and is critical for learning and memory.

Microtubule dynamics: The regulated assembly and disassembly of cytoskeletal filaments essential for intracellular transport and neuronal morphology.

References

1. Mapping Pathological Phenotypes in a Mouse Model of CDKL5 Disorder. PLOS ONE (2014).
2. Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics. The EMBO Journal (2018).
3. Epilepsy-linked kinase CDKL5 phosphorylates voltage-gated calcium channel Cav2.3, altering inactivation kinetics and neuronal excitability. Nature Communications (2023).
4. Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder. Nature Communications (2019).
5. There is variability in the attainment of developmental milestones in the CDKL5 disorder. Journal of Neurodevelopmental Disorders (2015).
6. Cell type-specific expression, regulation and compensation of CDKL5 activity in mouse brain. Molecular Psychiatry (2024).
7. Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome. Orphanet Journal of Rare Diseases (2016).